Your browser does not support JavaScript! For Patients | Biofidelity

For lung cancer patients, every day counts.

A young cancer patient in a matching scarf and shirt.

You deserve the best treatment available.

Targeted cancer therapies have dramatically improved survival rates1, but only patients who receive biomarker testing can benefit from them. And there are critical barriers to these tests throughout the patient journey.

Existing biomarker tests take weeks to deliver results. Many samples fail testing, requiring repeat biopsies and additional delays. And the process can cost thousands of dollars.

Aspyre Clinical Test for Lung gives you answers in days, not weeks.

The first application of the Aspyre technology, Aspyre Clinical Test for Lung enables fast, actionable treatment decisions for non-small cell lung cancer (NSCLC) patients.

Aspyre Clinical Test for Lung tests all guideline-recommended genes associated with targeted therapies for NSCLC.

An oncologist reviews test results on a laptop.

Aspyre Clinical Test for Lung enables fast, confident treatment decisions.

Aspyre Clinical Test for Lung simultaneously analyzes DNA and RNA from blood or tissue in a single assay, maximizing the opportunity to identify the treatments that are right for you, while avoiding the additional time and expense of running multiple tests.

Faster Time to Treatment

Results in just 2 days, compared to weeks with other tests.

Actionable Results

One test for all biomarkers that correlate with targeted therapies, giving you the best treatment options.

Simple & Cost-Effective

A fraction of the cost of existing biomarker tests, which are expensive and hard to interpret.

Patient Support

We believe every patient deserves the best treatment options. Aspyre Clinical Test for Lung gives you those options.

References

1. Tsimberidou AM, Sireci A, Dumanois R, et al: Strategies to Address the Clinical Practice Gaps Affecting the Implementation of Personalized Medicine in Cancer Care. JCO Oncol Pr 20:761–766, 2024